Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Methods to Make Homogenous Antibody Drug Conjugates

Presentations

Methods to Make Homogenous Antibody Drug Conjugates Toni Kline, Alexander R. Steiner, Kalyani Penta, Aaron K. Sato, Trevor J. Hallam, Gang Yin,  Methods to Make Homogenous Antibody Drug Conjugates Pharmaceutical Research December 2014, Read...

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Press Releases

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient...

FierceBiotech names Sutro Biopharma as one of its “Fierce 15” Biotech Companies of 2014

Events

FierceBiotech names Sutro Biopharma as one of its “Fierce 15” Biotech Companies of 2014   San Francisco, CA – September 22, 2014 – Sutro Biopharma today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies,...

A General Sequence Processing and Analysis Program for Protein Engineering

Presentations

A General Sequence Processing and Analysis Program for Protein Engineering Ryan L. Stafford,* Erik S. Zimmerman, Trevor J. Hallam, and Aaron K. Sato, A General Sequence Processing and Analysis Program for Protein Engineering, dx.doi.org/10.1021/ci500362s | J. Chem....

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates

Press Releases

Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates Collaboration and license agreement allows the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, to enhance its access to antibody drug conjugate...

Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member

Press Releases

Sutro Biopharma to Collaborate with University of California, San Francisco (UCSF), a Recombinant Antibody Network (RAN) Member Collaboration to Express Antibodies and Antigens based on Sutro’s Technology Platform XpressCF+™ SAN FRANCISCO, Sept. 9, 2014 – Sutro...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.